Status:
COMPLETED
Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
STI
Eligibility:
FEMALE
18-30 years
Phase:
PHASE4
Brief Summary
The first study of doxycycline postexposure prophylaxis for cisgender women did not reduce incident STIs likely due to low use of doxycycline. Researchers will conduct a pilot study of once-weekly dox...
Detailed Description
A study evaluating doxycycline prophylaxis to prevent sexually transmitted infections (STIs) in PrEP-taking African women, who are a priority population for STI prevention, given their high risk and e...
Eligibility Criteria
Inclusion
- Willing and able to give written informed consent
- Age 18-30 years
- Female sex assigned at birth
- HIV-seronegative, according to national HIV testing algorithm
- Has a current prescription for PrEP, \> 1 month, according to the national guidelines of Kenya
Exclusion
- Pregnant
- Breastfeeding a child
- Allergy to tetracycline class
- Current medications which may impact doxycycline metabolism or that are contraindicated with doxycycline, as per the prescribing information. These include systemic retinoids, barbiturates, carbamazepine, phenytoin, and warfarin.
- Active, clinically significant medical or psychiatric conditions that would interfere with study participation, at the discretion of the site investigator or designee.
- Prior enrollment in The dPEP Kenya Study
Key Trial Info
Start Date :
August 13 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06582966
Start Date
August 13 2024
End Date
December 31 2024
Last Update
February 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kenya Medical Research Institute -KEMRI
Kisumu, Kenya